JP2011522540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522540A5 JP2011522540A5 JP2011512634A JP2011512634A JP2011522540A5 JP 2011522540 A5 JP2011522540 A5 JP 2011522540A5 JP 2011512634 A JP2011512634 A JP 2011512634A JP 2011512634 A JP2011512634 A JP 2011512634A JP 2011522540 A5 JP2011522540 A5 JP 2011522540A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- differentiation
- ebna
- cell
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 416
- 239000013598 vector Substances 0.000 claims description 163
- 230000004069 differentiation Effects 0.000 claims description 139
- 238000000034 method Methods 0.000 claims description 124
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 claims description 114
- 108090000623 proteins and genes Proteins 0.000 claims description 113
- 230000008672 reprogramming Effects 0.000 claims description 91
- 230000010076 replication Effects 0.000 claims description 82
- 230000014509 gene expression Effects 0.000 claims description 72
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 71
- 241001529453 unidentified herpesvirus Species 0.000 claims description 64
- 210000000130 stem cell Anatomy 0.000 claims description 61
- 102000004169 proteins and genes Human genes 0.000 claims description 46
- 238000013518 transcription Methods 0.000 claims description 44
- 230000035897 transcription Effects 0.000 claims description 44
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 43
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 claims description 35
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 claims description 35
- 108091023040 Transcription factor Proteins 0.000 claims description 33
- 230000002068 genetic effect Effects 0.000 claims description 32
- 210000001082 somatic cell Anatomy 0.000 claims description 31
- 239000003550 marker Substances 0.000 claims description 30
- 230000037430 deletion Effects 0.000 claims description 23
- 238000012217 deletion Methods 0.000 claims description 23
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 22
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 22
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 22
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 19
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 19
- 101150111214 lin-28 gene Proteins 0.000 claims description 17
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims description 15
- 210000002950 fibroblast Anatomy 0.000 claims description 14
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 12
- -1 Nanog Proteins 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 11
- 241000701822 Bovine papillomavirus Species 0.000 claims description 10
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims description 10
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims description 9
- 241000282695 Saimiri Species 0.000 claims description 9
- 210000004748 cultured cell Anatomy 0.000 claims description 9
- 241000701161 unidentified adenovirus Species 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 8
- 210000001900 endoderm Anatomy 0.000 claims description 7
- 210000005260 human cell Anatomy 0.000 claims description 7
- 108020005091 Replication Origin Proteins 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 6
- 101150099612 Esrrb gene Proteins 0.000 claims description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 5
- 210000001178 neural stem cell Anatomy 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- 101000909637 Homo sapiens Transcription factor COE1 Proteins 0.000 claims description 4
- 102100024207 Transcription factor COE1 Human genes 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 claims description 4
- 108091006047 fluorescent proteins Proteins 0.000 claims description 4
- 102000034287 fluorescent proteins Human genes 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- 208000009889 Herpes Simplex Diseases 0.000 claims description 3
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 claims description 3
- 101100043062 Mus musculus Sox7 gene Proteins 0.000 claims description 3
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 3
- 102000001253 Protein Kinase Human genes 0.000 claims description 3
- 210000002510 keratinocyte Anatomy 0.000 claims description 3
- 108060006633 protein kinase Proteins 0.000 claims description 3
- 229940104230 thymidine Drugs 0.000 claims description 3
- 230000011712 cell development Effects 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 230000000392 somatic effect Effects 0.000 claims description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims 2
- 230000001926 lymphatic effect Effects 0.000 claims 2
- 210000005229 liver cell Anatomy 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 description 58
- 239000013612 plasmid Substances 0.000 description 52
- 102000039446 nucleic acids Human genes 0.000 description 44
- 108020004707 nucleic acids Proteins 0.000 description 44
- 210000001519 tissue Anatomy 0.000 description 43
- 108020004414 DNA Proteins 0.000 description 42
- 108090000765 processed proteins & peptides Proteins 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 30
- 102000004196 processed proteins & peptides Human genes 0.000 description 28
- 229920001184 polypeptide Polymers 0.000 description 26
- 150000001413 amino acids Chemical class 0.000 description 23
- 230000006870 function Effects 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 22
- 239000003623 enhancer Substances 0.000 description 20
- 239000002502 liposome Substances 0.000 description 20
- 210000001778 pluripotent stem cell Anatomy 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 19
- 241000700605 Viruses Species 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 19
- 230000008569 process Effects 0.000 description 17
- 239000008186 active pharmaceutical agent Substances 0.000 description 16
- 230000027455 binding Effects 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- 238000001890 transfection Methods 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000006698 induction Effects 0.000 description 15
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 14
- 238000012423 maintenance Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 13
- 230000032823 cell division Effects 0.000 description 12
- 230000008488 polyadenylation Effects 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 239000002157 polynucleotide Substances 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 206010043276 Teratoma Diseases 0.000 description 8
- 210000002459 blastocyst Anatomy 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000001177 retroviral effect Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000700584 Simplexvirus Species 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000002304 esc Anatomy 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000001161 mammalian embryo Anatomy 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 6
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 6
- 108020004440 Thymidine kinase Proteins 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000002257 embryonic structure Anatomy 0.000 description 6
- 210000001654 germ layer Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 210000003463 organelle Anatomy 0.000 description 6
- 230000003362 replicative effect Effects 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 108091029865 Exogenous DNA Proteins 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108010017842 Telomerase Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000001506 calcium phosphate Substances 0.000 description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 description 5
- 235000011010 calcium phosphates Nutrition 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000032459 dedifferentiation Effects 0.000 description 5
- 210000002242 embryoid body Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 230000006820 DNA synthesis Effects 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
- 244000187656 Eucalyptus cornuta Species 0.000 description 4
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 4
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000002716 delivery method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000011987 methylation Effects 0.000 description 4
- 238000007069 methylation reaction Methods 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000005030 transcription termination Effects 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 210000002993 trophoblast Anatomy 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 3
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 3
- 108091027981 Response element Proteins 0.000 description 3
- 101150086694 SLC22A3 gene Proteins 0.000 description 3
- 108700026226 TATA Box Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 230000002759 chromosomal effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000006471 dimerization reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 description 3
- 210000000299 nuclear matrix Anatomy 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000030648 nucleus localization Effects 0.000 description 3
- 230000006548 oncogenic transformation Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 2
- XUUXCWCKKCZEAW-YFKPBYRVSA-N Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100342337 Caenorhabditis elegans klf-1 gene Proteins 0.000 description 2
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 2
- 241000050051 Chelone glabra Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100036949 Developmental pluripotency-associated protein 2 Human genes 0.000 description 2
- 102100037126 Developmental pluripotency-associated protein 4 Human genes 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 2
- 102100037907 High mobility group protein B1 Human genes 0.000 description 2
- 101710168537 High mobility group protein B1 Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000804948 Homo sapiens Developmental pluripotency-associated protein 2 Proteins 0.000 description 2
- 101000881868 Homo sapiens Developmental pluripotency-associated protein 4 Proteins 0.000 description 2
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 2
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 2
- 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 101150072501 Klf2 gene Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 108010047357 Luminescent Proteins Proteins 0.000 description 2
- 102000006830 Luminescent Proteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 2
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 2
- 108091057508 Myc family Proteins 0.000 description 2
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 101710101305 Transducin-like enhancer protein 1 Proteins 0.000 description 2
- 102100039362 Transducin-like enhancer protein 1 Human genes 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 102100023550 Zinc finger protein 42 homolog Human genes 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000010307 cell transformation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 230000010502 episomal replication Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003500 gene array Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000001483 mobilizing effect Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000447 polyanionic polymer Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000000754 repressing effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001988 somatic stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108091008023 transcriptional regulators Proteins 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 239000010937 tungsten Substances 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- PSLCKQYQNVNTQI-BHFSHLQUSA-N (2s)-2-aminobutanedioic acid;(2s)-2-aminopentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O PSLCKQYQNVNTQI-BHFSHLQUSA-N 0.000 description 1
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical class OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- VVJYUAYZJAKGRQ-BGZDPUMWSA-N 1-[(2r,4r,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)C1 VVJYUAYZJAKGRQ-BGZDPUMWSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- 101710151768 Aromatic-L-amino-acid decarboxylase Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical group OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical group OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000049983 HMGA1a Human genes 0.000 description 1
- 108700039142 HMGA1a Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 102100022130 High mobility group protein B3 Human genes 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
- 101001006375 Homo sapiens High mobility group nucleosome-binding domain-containing protein 4 Proteins 0.000 description 1
- 101001045794 Homo sapiens High mobility group protein B3 Proteins 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101000984044 Homo sapiens LIM homeobox transcription factor 1-beta Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 101001120813 Homo sapiens Myosin regulatory light chain 2, atrial isoform Proteins 0.000 description 1
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 1
- 101000642523 Homo sapiens Transcription factor SOX-7 Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 102100025457 LIM homeobox transcription factor 1-beta Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 101100310645 Mus musculus Sox15 gene Proteins 0.000 description 1
- 101100310650 Mus musculus Sox18 gene Proteins 0.000 description 1
- 102100039229 Myocyte-specific enhancer factor 2C Human genes 0.000 description 1
- 102100026057 Myosin regulatory light chain 2, atrial isoform Human genes 0.000 description 1
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 description 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- NPKISZUVEBESJI-UHFFFAOYSA-N Nalpha-benzoyl-L-phenylalanine Natural products C=1C=CC=CC=1C(=O)NC(C(=O)O)CC1=CC=CC=C1 NPKISZUVEBESJI-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710150336 Protein Rex Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108700025832 Serum Response Element Proteins 0.000 description 1
- 101150001847 Sox15 gene Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101001081186 Tetrahymena pyriformis High mobility group protein Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 1
- 102100036730 Transcription factor SOX-7 Human genes 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 1
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000021040 cytoplasmic transport Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002907 exocrine cell Anatomy 0.000 description 1
- 210000000646 extraembryonic cell Anatomy 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 102000033952 mRNA binding proteins Human genes 0.000 description 1
- 108091000373 mRNA binding proteins Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007524 negative regulation of DNA replication Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- CQYBNXGHMBNGCG-RNJXMRFFSA-N octahydroindole-2-carboxylic acid Chemical compound C1CCC[C@H]2N[C@H](C(=O)O)C[C@@H]21 CQYBNXGHMBNGCG-RNJXMRFFSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000027086 plasmid maintenance Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000001164 retinal progenitor cell Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5885808P | 2008-06-04 | 2008-06-04 | |
| US61/058,858 | 2008-06-04 | ||
| US16058409P | 2009-03-16 | 2009-03-16 | |
| US61/160,584 | 2009-03-16 | ||
| PCT/US2009/046209 WO2009149233A1 (en) | 2008-06-04 | 2009-06-04 | Methods for the production of ips cells using non-viral approach |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014121146A Division JP2014209912A (ja) | 2008-06-04 | 2014-06-12 | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011522540A JP2011522540A (ja) | 2011-08-04 |
| JP2011522540A5 true JP2011522540A5 (enExample) | 2012-05-31 |
Family
ID=40977641
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512634A Pending JP2011522540A (ja) | 2008-06-04 | 2009-06-04 | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 |
| JP2014121146A Withdrawn JP2014209912A (ja) | 2008-06-04 | 2014-06-12 | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 |
| JP2017132684A Pending JP2018007667A (ja) | 2008-06-04 | 2017-07-06 | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 |
| JP2017132685A Pending JP2018019684A (ja) | 2008-06-04 | 2017-07-06 | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 |
| JP2020070205A Pending JP2020115881A (ja) | 2008-06-04 | 2020-04-09 | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014121146A Withdrawn JP2014209912A (ja) | 2008-06-04 | 2014-06-12 | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 |
| JP2017132684A Pending JP2018007667A (ja) | 2008-06-04 | 2017-07-06 | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 |
| JP2017132685A Pending JP2018019684A (ja) | 2008-06-04 | 2017-07-06 | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 |
| JP2020070205A Pending JP2020115881A (ja) | 2008-06-04 | 2020-04-09 | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8546140B2 (enExample) |
| EP (4) | EP3447128A1 (enExample) |
| JP (5) | JP2011522540A (enExample) |
| KR (2) | KR101871192B1 (enExample) |
| AU (1) | AU2009256202B2 (enExample) |
| CA (2) | CA2954948A1 (enExample) |
| DK (1) | DK2297307T3 (enExample) |
| ES (1) | ES2587395T3 (enExample) |
| IL (1) | IL209740A (enExample) |
| WO (1) | WO2009149233A1 (enExample) |
Families Citing this family (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090227032A1 (en) * | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| KR101420740B1 (ko) * | 2005-12-13 | 2014-07-17 | 교또 다이가꾸 | 핵초기화 인자 |
| EP2137296A2 (en) | 2007-03-23 | 2009-12-30 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
| JP2008307007A (ja) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| US9213999B2 (en) * | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
| ES2722198T3 (es) | 2008-05-02 | 2019-08-08 | Univ Kyoto | Método de reprogramación nuclear |
| EP3447128A1 (en) | 2008-06-04 | 2019-02-27 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of ips cells using non-viral approach |
| CN105671065A (zh) * | 2008-06-13 | 2016-06-15 | 怀特黑德生物医学研究所 | 细胞编程和重编程 |
| CN102171348A (zh) * | 2008-08-12 | 2011-08-31 | 细胞动力国际有限公司 | 产生ips细胞的方法 |
| EP3450545B1 (en) * | 2008-10-24 | 2023-08-23 | Wisconsin Alumni Research Foundation | Pluripotent stem cells obtained by non-viral reprogramming |
| WO2011071476A2 (en) * | 2008-11-14 | 2011-06-16 | Life Technologies Corporation | Compositions and methods for engineering cells |
| WO2010124142A2 (en) | 2009-04-22 | 2010-10-28 | Cythera, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| CN103087991B (zh) | 2009-06-05 | 2018-06-12 | 富士胶片细胞动力公司 | 重编程t细胞和造血细胞的方法 |
| WO2011016588A1 (en) | 2009-08-07 | 2011-02-10 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| JP5880868B2 (ja) | 2009-09-30 | 2016-03-09 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 核内受容体及びその変異体、並びに細胞の再プログラミングにおけるその使用 |
| ES2539487T3 (es) * | 2009-11-04 | 2015-07-01 | Cellular Dynamics International, Inc. | Reprogramación episómica con compuestos químicos |
| WO2011119942A1 (en) * | 2010-03-25 | 2011-09-29 | Vistagen Therapeutics, Inc. | Induction of ips cells using transient episomal vectors |
| AU2011235212B2 (en) | 2010-03-31 | 2014-07-31 | The Scripps Research Institute | Reprogramming cells |
| US8048675B1 (en) | 2010-05-12 | 2011-11-01 | Ipierian, Inc. | Integration-free human induced pluripotent stem cells from blood |
| US8691574B2 (en) | 2010-06-15 | 2014-04-08 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
| WO2011159797A2 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | A compendium of ready-built stem cell models for interrogation of biological response |
| KR101861171B1 (ko) | 2010-06-18 | 2018-05-31 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 투석된 혈청이 있는 심근세포 배지 |
| US8765470B2 (en) | 2010-08-04 | 2014-07-01 | Cellular Dynamics International, Inc. | Reprogramming immortalized B-cells to induced pluripotent stem cells |
| US20130309209A1 (en) * | 2010-10-22 | 2013-11-21 | Center For Regenerative Medicine Of Barcelona | Formation of hematopoietic progenitor cells from mesenchymal stem cells |
| EP2673358B1 (en) | 2011-02-08 | 2019-01-09 | FUJIFILM Cellular Dynamics, Inc. | Hematopoietic precursor cell production by programming |
| US9228204B2 (en) | 2011-02-14 | 2016-01-05 | University Of Utah Research Foundation | Constructs for making induced pluripotent stem cells |
| EP4086338A1 (en) | 2011-03-17 | 2022-11-09 | Minerva Biotechnologies Corporation | Method for making pluripotent stem cells |
| WO2012159079A1 (en) | 2011-05-18 | 2012-11-22 | The Parkinson's Institute | Assay to determine lrrk2 activity in parkinson's disease |
| JP2014520551A (ja) * | 2011-07-11 | 2014-08-25 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 細胞のリプログラミング方法およびゲノムの改変方法 |
| WO2013022022A1 (ja) * | 2011-08-08 | 2013-02-14 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
| WO2013059373A2 (en) | 2011-10-17 | 2013-04-25 | Minerva Biotechnologies Corporation | Media for stem cell proliferation and induction |
| US8497124B2 (en) | 2011-12-05 | 2013-07-30 | Factor Bioscience Inc. | Methods and products for reprogramming cells to a less differentiated state |
| DK3260140T3 (da) | 2011-12-05 | 2021-04-19 | Factor Bioscience Inc | Fremgangsmåder og produkter til transficering af celler |
| EP2826855B1 (en) | 2012-03-15 | 2018-08-29 | iHeart Japan Corporation | Myocardial sheet |
| JP6335117B2 (ja) | 2012-03-21 | 2018-05-30 | 国立大学法人京都大学 | アルツハイマー病の治療薬および／または予防薬のスクリーニング方法 |
| US9334475B2 (en) | 2012-04-06 | 2016-05-10 | Kyoto University | Method for inducing erythropoietin-producing cell |
| WO2013159103A1 (en) * | 2012-04-20 | 2013-10-24 | Whitehead Institute For Biomedical Research | Programming and reprogramming of cells |
| JP6084605B2 (ja) | 2012-04-27 | 2017-02-22 | 日野自動車株式会社 | バーナー、および、フィルター再生装置 |
| EP2853592B1 (en) * | 2012-05-23 | 2019-02-20 | Kyoto University | Highly efficient method for establishing artificial pluripotent stem cell |
| US9175263B2 (en) | 2012-08-22 | 2015-11-03 | Biotime, Inc. | Methods and compositions for targeting progenitor cell lines |
| US9382531B2 (en) | 2012-10-22 | 2016-07-05 | Wisconsin Alumni Research Foundation | Induction of hemogenic endothelium from pluripotent stem cells |
| BR122019025681B1 (pt) | 2012-11-01 | 2023-04-18 | Factor Bioscience Inc | Método para inserir uma sequência de ácido nucleico em uma localização segura de um genoma de uma célula |
| US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
| US10266807B2 (en) | 2013-04-03 | 2019-04-23 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
| EP2986713A1 (en) * | 2013-04-16 | 2016-02-24 | Glykos Finland Oy | A method for generating induced pluripotent stem cells |
| EP3003290B1 (en) | 2013-06-05 | 2021-03-10 | AgeX Therapeutics, Inc. | Compositions for use in the treatment of wounds in mammalian species |
| WO2014197934A1 (en) | 2013-06-14 | 2014-12-18 | The University Of Queensland | Renal progenitor cells |
| CN103333918B (zh) * | 2013-06-19 | 2015-12-02 | 中山大学 | 一种提高猪克隆胚胎体外发育效率的方法 |
| WO2015006725A2 (en) | 2013-07-12 | 2015-01-15 | Cedars-Sinai Medical Center | Generation of induced pluripotent stem cells from normal human mammary epithelial cells |
| JP6536871B2 (ja) | 2013-12-02 | 2019-07-03 | 国立大学法人京都大学 | Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法 |
| US9988605B2 (en) | 2013-12-11 | 2018-06-05 | Korea Advanced Institute Of Science And Technology | Method for preparing endocrine aggregate of insulin-producing beta cells from human pluripotent stem cells |
| WO2015117021A1 (en) | 2014-01-31 | 2015-08-06 | Factor Bioscience Inc. | Methods and products for nucleic acid production and delivery |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| CA2945393C (en) | 2014-04-24 | 2021-03-23 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| US10947500B2 (en) | 2014-06-27 | 2021-03-16 | Angiocrine Bioscience, Inc. | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| EP3183338B1 (en) | 2014-08-19 | 2020-03-04 | FUJIFILM Cellular Dynamics, Inc. | Neural networks formed from cells derived from pluripotent stem cells |
| EP3207122B1 (en) | 2014-10-14 | 2019-05-08 | FUJIFILM Cellular Dynamics, Inc. | Generation of keratinocytes from pluripotent stem cells and maintenance of keratinocyte cultures |
| US9828634B2 (en) | 2015-01-22 | 2017-11-28 | Regenerative Medical Solutions, Inc. | Markers for differentiation of stem cells into differentiated cell populations |
| EP3543339A1 (en) | 2015-02-13 | 2019-09-25 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| AU2016318774B2 (en) | 2015-09-08 | 2022-08-18 | FUJIFILM Cellular Dynamics, Inc. | MACS-based purification of stem cell-derived retinal pigment epithelium |
| ES2970537T3 (es) | 2015-09-08 | 2024-05-29 | Us Health | Método para la diferenciación reproducible de células epiteliales del pigmento retiniano de calidad clínica |
| US10865381B2 (en) | 2015-10-20 | 2020-12-15 | FUJIFILM Cellular Dynamics, Inc. | Multi-lineage hematopoietic precursor cell production by genetic programming |
| JP2018536438A (ja) | 2015-12-07 | 2018-12-13 | バイオタイム，インコーポレーテッド | 多様な多能性幹細胞から誘導された褐色脂肪細胞の再誘導のための方法 |
| CA3010764A1 (en) * | 2016-01-12 | 2017-07-20 | Lonza Walkersville, Inc. | Methods and vectors to produce vector free induced pluripotent stem cells |
| WO2017196175A1 (en) | 2016-05-12 | 2017-11-16 | Erasmus University Medical Center Rotterdam | A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium. |
| US10221395B2 (en) | 2016-06-16 | 2019-03-05 | Cedars-Sinai Medical Center | Efficient method for reprogramming blood to induced pluripotent stem cells |
| US11572545B2 (en) | 2016-06-16 | 2023-02-07 | Cedars-Sinai Medical Center | Efficient method for reprogramming blood to induced pluripotent stem cells |
| US20180030478A1 (en) | 2016-07-01 | 2018-02-01 | Research Development Foundation | Elimination of proliferating cells from stem cell-derived grafts |
| WO2018035214A1 (en) | 2016-08-16 | 2018-02-22 | Cellular Dynamics International., Inc. | Methods for differentiating pluripotent cells |
| CN109803977B (zh) | 2016-08-17 | 2023-03-17 | 菲克特生物科学股份有限公司 | 核酸产品及其施用方法 |
| JP2019537729A (ja) | 2016-09-28 | 2019-12-26 | オルガノボ インコーポレイテッド | アッセイにおける人工腎臓組織の使用 |
| ES3009605T3 (en) | 2016-10-05 | 2025-03-27 | Fujifilm Cellular Dynamics Inc | Generating mature lineages from induced pluripotent stem cells with mecp2 disruption |
| WO2018089515A1 (en) | 2016-11-09 | 2018-05-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 3d vascularized human ocular tissue for cell therapy and drug discovery |
| MX2019011897A (es) | 2017-04-18 | 2019-11-28 | Fujifilm Cellular Dynamics Inc | Celulas efectoras inmunitarias especificas de antigenos. |
| NL2019517B1 (en) | 2017-09-08 | 2019-03-19 | Univ Erasmus Med Ct Rotterdam | New therapy for Pompe disease |
| EP3692139B1 (en) | 2017-10-03 | 2024-11-06 | SDF BioPharma Inc. | Treating diabetes with genetically modified beta cells |
| CA3078734A1 (en) | 2017-10-11 | 2019-04-18 | Fate Therapeutics, Inc. | Cellular reprogramming using temporal and transient plasmid vector expression system |
| GB201805683D0 (en) * | 2018-04-05 | 2018-05-23 | Touchlight Ip Ltd | Reprogramming vectors |
| AU2019256723B2 (en) | 2018-04-20 | 2025-09-04 | FUJIFILM Cellular Dynamics, Inc. | Method for differentiation of ocular cells and use thereof |
| AU2019347666B2 (en) | 2018-09-28 | 2025-10-02 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| KR20210095885A (ko) | 2018-11-19 | 2021-08-03 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 생분해성 조직 대체 임플란트 및 그의 용도 |
| AU2019386140A1 (en) | 2018-11-28 | 2021-06-24 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
| CN113316455A (zh) | 2018-11-29 | 2021-08-27 | 得克萨斯大学体系董事会 | 用于离体扩增自然杀伤细胞的方法及其用途 |
| WO2020237104A1 (en) * | 2019-05-23 | 2020-11-26 | The Mclean Hospital Corporation | Autologous cell replacement therapy for parkinson's disease |
| US12410401B2 (en) | 2019-06-06 | 2025-09-09 | Wisconsin Alumni Research Foundation (Warf) | Generation of functional neutrophils and macrophages from induced pluripotent stem cells in chemically defined conditions using transient expression of ETV2 |
| WO2021003462A1 (en) | 2019-07-03 | 2021-01-07 | Factor Bioscience Inc. | Cationic lipids and uses thereof |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| EP4074321A4 (en) | 2019-12-12 | 2024-01-03 | National University Corporation Chiba University | Freeze-dried preparation containing megakaryocytes and platelets |
| US20230212509A1 (en) | 2020-05-29 | 2023-07-06 | FUJIFILM Cellular Dynamics, Inc. | Bilayer of retinal pigmented epithelium and photoreceptors and use thereof |
| JP2023528377A (ja) | 2020-05-29 | 2023-07-04 | フジフィルム セルラー ダイナミクス，インコーポレイテッド | 網膜色素上皮及び光受容体の二重細胞凝集体、並びにその使用方法 |
| EP3922431A1 (en) | 2020-06-08 | 2021-12-15 | Erasmus University Medical Center Rotterdam | Method of manufacturing microdevices for lab-on-chip applications |
| US20230374452A1 (en) | 2020-10-07 | 2023-11-23 | Mican Technologies Inc. | Coronavirus-infective cells and method of preparing same |
| AU2021377699A1 (en) | 2020-11-13 | 2023-06-15 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| AU2021388155A1 (en) | 2020-11-25 | 2023-06-15 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| EP4314249A1 (en) * | 2021-03-25 | 2024-02-07 | Bluerock Therapeutics LP | Methods for obtaining induced pluripotent stem cells |
| JP2024519515A (ja) | 2021-04-07 | 2024-05-15 | センチュリー セラピューティクス，インコーポレイテッド | 人工多能性幹細胞からガンマ－デルタｔ細胞を生成するための組成物および方法 |
| WO2022216524A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof |
| US20240219375A1 (en) | 2021-04-07 | 2024-07-04 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic precursor cells and methods of use |
| CN117441010A (zh) | 2021-04-07 | 2024-01-23 | 世纪治疗股份有限公司 | 从诱导多能干细胞产生α-βT细胞的组合物和方法 |
| CA3210702A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Gene transfer vectors and methods of engineering cells |
| KR20240011831A (ko) | 2021-05-26 | 2024-01-26 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 만능 줄기 세포에서 유전자의 신속한 사일런싱을 방지하기 위한 방법 |
| US20240271089A1 (en) | 2021-05-28 | 2024-08-15 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Methods to generate macular, central and peripheral retinal pigment epithelial cells |
| US20240261474A1 (en) | 2021-05-28 | 2024-08-08 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Biodegradable tissue scaffold with secondary matrix to host weakly adherent cells |
| JP2024531682A (ja) | 2021-09-13 | 2024-08-29 | フジフィルム セルラー ダイナミクス，インコーポレイテッド | コミットされた心臓始原細胞の製造方法 |
| CN118339279A (zh) | 2021-10-29 | 2024-07-12 | 富士胶片细胞动力公司 | 包含突变的多巴胺能神经元及其使用方法 |
| EP4456912A1 (en) | 2021-12-29 | 2024-11-06 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
| WO2023172514A1 (en) | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
| WO2023196577A1 (en) * | 2022-04-08 | 2023-10-12 | New York Stem Cell Foundation, Inc. | Methods for production of ipscs |
| CN119365492A (zh) | 2022-05-04 | 2025-01-24 | 世纪治疗股份有限公司 | 用hla-e和hla-g转基因工程化的细胞 |
| CN119630695A (zh) | 2022-06-08 | 2025-03-14 | 世纪治疗股份有限公司 | 表达cd16变体和nkg2d的遗传工程化细胞及其用途 |
| WO2023240169A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof |
| US20250090582A1 (en) | 2022-06-08 | 2025-03-20 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof |
| WO2023247532A1 (en) | 2022-06-21 | 2023-12-28 | Institut National de la Santé et de la Recherche Médicale | A method for producing a bioengineered mammal induced pluripotent stem cell-derived cardiac organoid |
| US20240003871A1 (en) | 2022-06-29 | 2024-01-04 | FUJIFILM Cellular Dynamics, Inc. | Ipsc-derived astrocytes and methods of use thereof |
| WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
| WO2024102838A1 (en) | 2022-11-09 | 2024-05-16 | Century Therapeutics, Inc. | Engineered interleukin-7 receptors and uses thereof |
| WO2024103017A2 (en) | 2022-11-10 | 2024-05-16 | Century Therapeutics, Inc. | Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof |
| WO2024192329A1 (en) | 2023-03-16 | 2024-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for producing stable human chondroctyes and their use for promoting cartillage growth and repair |
| WO2025101938A2 (en) | 2023-11-10 | 2025-05-15 | Century Therapeutics, Inc. | Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof |
| WO2025106626A1 (en) | 2023-11-15 | 2025-05-22 | Century Therapeutics, Inc. | Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof |
| WO2025207795A1 (en) | 2024-03-26 | 2025-10-02 | Juno Therapeutics, Inc. | Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof |
| WO2025207798A1 (en) | 2024-03-26 | 2025-10-02 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof |
| WO2025245202A1 (en) | 2024-05-21 | 2025-11-27 | FUJIFILM Cellular Dynamics, Inc. | Particle counting and biomass measurements of aggregated cell compositions |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
| US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
| US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| DE69334225D1 (de) | 1992-07-07 | 2008-07-31 | Japan Tobacco Inc | Verfahren zur transformation einer monokotyledon pflanze |
| US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
| EP0652965A1 (en) | 1992-07-27 | 1995-05-17 | Pioneer Hi-Bred International, Inc. | An improved method of agrobacterium-mediated transformation of cultured soybean cells |
| DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
| DE19635568C1 (de) * | 1996-09-02 | 1998-03-26 | Gsf Forschungszentrum Umwelt | Vektorsysteme zur konditionalen Genexpression |
| US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
| US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
| EP1025204A4 (en) | 1997-10-23 | 2001-02-28 | Geron Corp | Methods and materials for the growth of primate-derived primordial stem cells |
| US20040199935A1 (en) | 1999-06-30 | 2004-10-07 | Chapman Karen B. | Cytoplasmic transfer to de-differentiate recipient cells |
| WO2001096532A2 (en) | 2000-06-15 | 2001-12-20 | Tanja Dominko | Method of generating pluripotent mammalian cells by fusion of a cytoplast fragment with a karyoplast |
| US20040235173A1 (en) | 2000-07-03 | 2004-11-25 | Gala Design, Inc. | Production of host cells containing multiple integrating vectors by serial transduction |
| US20020136709A1 (en) | 2000-12-12 | 2002-09-26 | Nucleus Remodeling, Inc. | In vitro-derived adult pluripotent stem cells and uses therefor |
| US20030211603A1 (en) | 2001-08-14 | 2003-11-13 | Earp David J. | Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells |
| US20030044976A1 (en) | 2001-08-27 | 2003-03-06 | Advanced Cell Technology | De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
| JP2004248505A (ja) * | 2001-09-21 | 2004-09-09 | Norio Nakatsuji | 移植抗原の一部または全てを欠除したｅｓ細胞由来の未分化な体細胞融合細胞およびその製造 |
| ITMI20012110A1 (it) | 2001-10-12 | 2003-04-12 | Keryos Spa | Vettori multi-cistronici utilizzabili in protocolli di trsferimento genico |
| WO2003056019A1 (en) * | 2001-12-24 | 2003-07-10 | Es Cell International Pte Ltd | Method of transducing es cells |
| GB0202149D0 (en) | 2002-01-30 | 2002-03-20 | Univ Edinburgh | Pluripotency determining factors and uses thereof |
| GB0206357D0 (en) * | 2002-03-18 | 2002-05-01 | Univ Bath | Cells |
| CA2515108A1 (en) | 2003-02-07 | 2004-08-26 | Wisconsin Alumni Research Foundation | Directed genetic modifications of human stem cells |
| US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
| KR100484653B1 (ko) | 2004-05-06 | 2005-04-20 | 주식회사 대웅 | 원핵세포에서 활성형의 가용성 단백질을 제조하는 방법 및 이를 위한 폴리시스트론 벡터 |
| US7465580B2 (en) | 2004-05-19 | 2008-12-16 | Wisconsin Alumni Research Foundation | Non-cytotoxic oriP replicon |
| US7442548B2 (en) | 2004-09-08 | 2008-10-28 | Wisconsin Alumni Research Foundation | Culturing human embryonic stem cells in medium containing pipecholic acid and gamma amino butyric acid |
| US20070087437A1 (en) | 2005-10-14 | 2007-04-19 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
| KR101420740B1 (ko) | 2005-12-13 | 2014-07-17 | 교또 다이가꾸 | 핵초기화 인자 |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| JP4803584B2 (ja) * | 2006-02-08 | 2011-10-26 | 独立行政法人産業技術総合研究所 | 脂質生産性の高い形質転換微生物 |
| TW200817512A (en) | 2006-07-07 | 2008-04-16 | Kirin Pharma Kk | Human artificial chromosome (hac) vector, and human cell pharmaceutical comprising human artificial chromosome (hac) vector |
| US20100137202A1 (en) | 2006-07-19 | 2010-06-03 | University Of Florida Research Foundation | Compositions for reprogramming a cell and uses therefor |
| US20110318792A1 (en) | 2006-08-15 | 2011-12-29 | Ishihara Sangyo Kaisha, Ltd. | Novel method for utilization of microbial mutant |
| JP2008067693A (ja) * | 2006-08-15 | 2008-03-27 | Ishihara Sangyo Kaisha Ltd | 微生物変異体の新規利用方法 |
| WO2008033469A1 (en) | 2006-09-15 | 2008-03-20 | Children's Medical Center Corporation | Methods for producing embryonic stem cells from parthenogenetic embryos |
| EP2137296A2 (en) | 2007-03-23 | 2009-12-30 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
| SG10201903161XA (en) | 2007-05-29 | 2019-05-30 | Christopher Reid | Methods for production and uses of multipotent cell populations |
| CN101802172A (zh) * | 2007-05-30 | 2010-08-11 | 通用医疗公司 | 由体细胞产生多能细胞的方法 |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| US20120282229A1 (en) | 2007-08-01 | 2012-11-08 | Christian Kannemeier | Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state |
| EP3078738B1 (en) | 2007-08-31 | 2020-05-20 | Whitehead Institute for Biomedical Research | Wnt pathway stimulation in reprogramming somatic cells |
| KR101564044B1 (ko) | 2007-10-31 | 2015-10-28 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 핵초기화 방법 |
| US20110151447A1 (en) | 2007-11-06 | 2011-06-23 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells |
| US9005966B2 (en) | 2007-11-19 | 2015-04-14 | The Regents Of The University Of California | Generation of pluripotent cells from fibroblasts |
| EP2072618A1 (en) * | 2007-12-14 | 2009-06-24 | Johannes Gutenberg-Universität Mainz | Use of RNA for reprogramming somatic cells |
| WO2009091543A1 (en) | 2008-01-14 | 2009-07-23 | Lindner Scott E | An efficient orip/ebna-1 plasmid vector |
| WO2009092042A1 (en) | 2008-01-18 | 2009-07-23 | Nevada Cancer Institute | Reprogramming of differentiated progenitor or somatic cells using homologous recombination |
| US20110061118A1 (en) * | 2008-03-17 | 2011-03-10 | Helmholtz Zentrum Munchen | Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination |
| ES2722198T3 (es) * | 2008-05-02 | 2019-08-08 | Univ Kyoto | Método de reprogramación nuclear |
| EP3447128A1 (en) | 2008-06-04 | 2019-02-27 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of ips cells using non-viral approach |
| WO2009157201A1 (en) | 2008-06-26 | 2009-12-30 | Osaka University | Method and kit for preparing ips cells |
| WO2010012077A1 (en) | 2008-07-28 | 2010-02-04 | Mount Sinai Hospital | Compositions, methods and kits for reprogramming somatic cells |
| CN102171348A (zh) | 2008-08-12 | 2011-08-31 | 细胞动力国际有限公司 | 产生ips细胞的方法 |
| WO2010028019A2 (en) * | 2008-09-03 | 2010-03-11 | The General Hospital Corporation | Direct reprogramming of somatic cells using non-integrating vectors |
| EP3450545B1 (en) | 2008-10-24 | 2023-08-23 | Wisconsin Alumni Research Foundation | Pluripotent stem cells obtained by non-viral reprogramming |
-
2009
- 2009-06-04 EP EP18187583.2A patent/EP3447128A1/en not_active Withdrawn
- 2009-06-04 EP EP09759392.5A patent/EP2297307B1/en not_active Revoked
- 2009-06-04 US US12/478,154 patent/US8546140B2/en active Active
- 2009-06-04 JP JP2011512634A patent/JP2011522540A/ja active Pending
- 2009-06-04 WO PCT/US2009/046209 patent/WO2009149233A1/en not_active Ceased
- 2009-06-04 KR KR1020167005088A patent/KR101871192B1/ko active Active
- 2009-06-04 KR KR1020107029686A patent/KR101648019B1/ko active Active
- 2009-06-04 DK DK09759392.5T patent/DK2297307T3/en active
- 2009-06-04 ES ES09759392.5T patent/ES2587395T3/es active Active
- 2009-06-04 CA CA2954948A patent/CA2954948A1/en not_active Abandoned
- 2009-06-04 CA CA2726990A patent/CA2726990C/en active Active
- 2009-06-04 EP EP17179349.0A patent/EP3279314A1/en not_active Withdrawn
- 2009-06-04 EP EP16165367.0A patent/EP3112456A1/en not_active Withdrawn
- 2009-06-04 AU AU2009256202A patent/AU2009256202B2/en active Active
-
2010
- 2010-12-02 IL IL209740A patent/IL209740A/en active IP Right Grant
-
2013
- 2013-03-11 US US13/794,297 patent/US9644184B2/en active Active
- 2013-08-07 US US13/961,858 patent/US9328332B2/en active Active
-
2014
- 2014-06-12 JP JP2014121146A patent/JP2014209912A/ja not_active Withdrawn
-
2017
- 2017-07-06 JP JP2017132684A patent/JP2018007667A/ja active Pending
- 2017-07-06 JP JP2017132685A patent/JP2018019684A/ja active Pending
- 2017-12-15 US US15/844,497 patent/US20180340150A1/en not_active Abandoned
-
2020
- 2020-04-09 JP JP2020070205A patent/JP2020115881A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020115881A (ja) | 非ウイルスアプローチを用いたｉＰＳ細胞の産生のための方法 | |
| JP2011522540A5 (enExample) | ||
| AU2009282133B2 (en) | Methods for the Production of IPS Cells | |
| KR20180105670A (ko) | 벡터-프리 유도만능 줄기세포를 생성시키기 위한 방법 및 벡터 | |
| AU2018200001A1 (en) | Methods for the production of ips cells | |
| HK1262665A1 (en) | Methods and vectors to produce vector free induced pluripotent stem cells |